Nikolai A. Podoltsev

Nov 7, 2023 | nature.com | Guillermo Garcia-Manero |Nikolai A. Podoltsev |Megan Othus |John Pagel |David A. Rizzieri |Guido Marcucci | +7 more

AbstractPrior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a randomized multicenter trial for previously untreated patients aged 18–60 with AML which compared daunorubicin and cytarabine (DA), idarubicin with higher dose cytarabine (IA) and IA with vorinostat (IA + V). The primary endpoint was event free survival (EFS).